 |
인쇄하기
취소
|
Cellbiotech Introduces Novel Anti-Hyperlipidemic Agent
Cellbiotech Co., a domestic biotechnology venture company, announced this week that it has successfully completed a pre-clinical animal study for a novel anti-hyperlipidemic agent known as PROLAC-T.
Jointly performed with the Konkuk University, results from the animal study showed that PROLAC-T, a type of anti-microbial peptides, reduced the amount of LDL (low density lipoprotein) cholestero...
Jointly performed with the Konkuk University, results from the animal study showed that PROLAC-T, a type of anti-microbial peptides, reduced the amount of LDL (low density lipoprotein) cholestero...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.